Advinia Health Care

Advinia is a network of care homes providing the full spectrum of care services. Our senior management team has been involved in care since 1999 and works in partnership with staff, residents, family and social workers. We know choosing a care home is a difficult decision, and we pride ourselves on providing homely facilities without an institutional feel.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

IMMUNOTEK BIO CENTERS FIRST TO LAUNCH VEINVIEWER® TECHNOLOGY FOR PLASMA DONATIONS

ImmunoTek Bio Centers | April 27, 2022

news image

Donating plasma is now easier, thanks to a smart new tool allowing technicians to see the map of veins inside a plasma donor's arm. ImmunoTek Bio Centers proudly announces its two divisions – ImmunoTek Plasma and Freedom Plasma – are the first blood plasma collection centers to use this groundbreaking technology. The VeinViewer®, developed by Christie Medical Holdings, has had great success in hospitals and medical clinics, and recently in pilot programs with ImmunoTek. Using...

Read More

MEDICAL

GENELUX AND NEWSOARA ANNOUNCE COLLABORATION AND LICENSE AGREEMENT FOR ONCOLYTIC IMMUNOTHERAPIES

Genelux Corporation | September 29, 2021

news image

Genelux Corporation, a clinical-stage immunotherapy company, and Newsoara BioPharma Co., Ltd., announced a collaboration and exclusive license for the development and commercialization of Olvi-Vec and other oncolytic viruses. According to the terms of the agreement, Newsoara shall have exclusive rights in Greater China (mainland China, Hong Kong, Macau and Taiwan) to Olvi-Vec for which Genelux currently is planning a U.S. based Phase 3 registration trial in platinum resistant/refr...

Read More

REGENERON STARTS PHASE REGN-COV2 PHASE 3 COVID-19 PREVENTION TRIAL

Regeneron | July 07, 2020

news image

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the initiation of late-stage clinical trials evaluating REGN-COV2, Regeneron's investigational double antibody cocktail for the treatment and prevention of COVID-19. A Phase 3 trial will evaluate REGN-COV2's ability to prevent infection among uninfected people who have had close exposure to a COVID-19 patient (such as the patient's housemate), and is being run jointly with the National Institute of Allergy and Infectious ...

Read More

SMART MONEY IS RACING INTO THE BIOTECH BOOM

FN Media Group | May 08, 2020

news image

The biotech boom is back. After its big breakthrough a few years ago, the biotech industry fell silent. Now, it is in the spotlight once again as smart money races in to back some once-in-a-generation breakthroughs. Mentioned in today's commentary includes: CRISPR Therapeutics AG (NASDAQ: CRSP), Sangamo Therapeutics, Inc. (NASDAQ: SGMO), Microsoft Corporation (NASDAQ: MSFT), International Business Machines Corporation (NYSE: IBM), Apple Inc. (NASDAQ: AAPL).From exciti...

Read More
news image

MEDICAL

IMMUNOTEK BIO CENTERS FIRST TO LAUNCH VEINVIEWER® TECHNOLOGY FOR PLASMA DONATIONS

ImmunoTek Bio Centers | April 27, 2022

Donating plasma is now easier, thanks to a smart new tool allowing technicians to see the map of veins inside a plasma donor's arm. ImmunoTek Bio Centers proudly announces its two divisions – ImmunoTek Plasma and Freedom Plasma – are the first blood plasma collection centers to use this groundbreaking technology. The VeinViewer®, developed by Christie Medical Holdings, has had great success in hospitals and medical clinics, and recently in pilot programs with ImmunoTek. Using...

Read More
news image

MEDICAL

GENELUX AND NEWSOARA ANNOUNCE COLLABORATION AND LICENSE AGREEMENT FOR ONCOLYTIC IMMUNOTHERAPIES

Genelux Corporation | September 29, 2021

Genelux Corporation, a clinical-stage immunotherapy company, and Newsoara BioPharma Co., Ltd., announced a collaboration and exclusive license for the development and commercialization of Olvi-Vec and other oncolytic viruses. According to the terms of the agreement, Newsoara shall have exclusive rights in Greater China (mainland China, Hong Kong, Macau and Taiwan) to Olvi-Vec for which Genelux currently is planning a U.S. based Phase 3 registration trial in platinum resistant/refr...

Read More
news image

REGENERON STARTS PHASE REGN-COV2 PHASE 3 COVID-19 PREVENTION TRIAL

Regeneron | July 07, 2020

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the initiation of late-stage clinical trials evaluating REGN-COV2, Regeneron's investigational double antibody cocktail for the treatment and prevention of COVID-19. A Phase 3 trial will evaluate REGN-COV2's ability to prevent infection among uninfected people who have had close exposure to a COVID-19 patient (such as the patient's housemate), and is being run jointly with the National Institute of Allergy and Infectious ...

Read More
news image

SMART MONEY IS RACING INTO THE BIOTECH BOOM

FN Media Group | May 08, 2020

The biotech boom is back. After its big breakthrough a few years ago, the biotech industry fell silent. Now, it is in the spotlight once again as smart money races in to back some once-in-a-generation breakthroughs. Mentioned in today's commentary includes: CRISPR Therapeutics AG (NASDAQ: CRSP), Sangamo Therapeutics, Inc. (NASDAQ: SGMO), Microsoft Corporation (NASDAQ: MSFT), International Business Machines Corporation (NYSE: IBM), Apple Inc. (NASDAQ: AAPL).From exciti...

Read More